proteins including the nuclear antigens (EBNA) and latent membrane proteins (LMP) are expressed with, in general, a cessation of the production of the BMRFl/p50 and BHRFl/pl7 proteins. Periodically, the virus is reactivated and one of the first proteins to be induced is p50 [20] .
The salivary glands are a reservoir for EBV, where it can induce a lymphoproliferative disease, which is usually transient. Because a major site of pathology in Sjogren's syndrome (SS) of dry eyes and dry mouth coincides with this site of EBV infectivity, it has long been speculated that EBV may contribute to the pathogenesis of the disease [1, 7, 14] . Other viruses, such as cytomegalovirus (CMV), human herpes virus 6 (HHV-6), HTLV and HIV, have also been detected in the salivary glands and/or saliva [4, 10, 13, 14] , and it is likely that such viruses may influence the inflammatory process at this site. SS can be the only rheumatic disease present, in which case it is referred to as primary SS, or it may be secondary to another disease such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), when it is referred to as secondary SS. It is, thus, not surprising that the EBV genome can be detected in the salivary tissue or whole saliva of patients with SS and, in addition, it can also be detected in patients with other rheumatic diseases without symptoms of SS, as well as in normal controls [13, 14, 21] . In a small subpopulation of patients, SS appears to develop in the absence of known viruses [14] .
One of the consequences of SS (both primary and secondary) is the 40-fold increased risk of lymphoma development [22] [23] [24] [25] [26] . With the recent demonstration that bcl-2 is associated with lymphoma [27] and the development of SLE-like disease in bcl-2 transgenic mice [28] , it became important to see whether the EBV homologue to bcl-2 played a similar role in rheumatic diseases of man. Since it had previously been shown that an immune response (B cell and T cell) to BHRFl/pl7 was detected in patients with nonHodgkin's lymphoma and Burkitt's lymphoma [29] , we have determined whether a similar immune response could be detected in patients with rheumatic diseases, focusing on patients with SS and lymphoma.
had B-cell lymphomas, six had T-cell lymphomas and the remaining seven had other neoplasias.
At the time of study, the sera from the SLE patients were tested for the presence of antinuclear antibodies (ANA), antibodies directed against Ro/SS-A, La/SS-B by ELISA (Therestest, Chicago, IL, USA), and DNA. Total serum IgG values were available for the RA and SLE patients. IgM rheumatoid factor (RF) was assayed by nephelometry for the RA group and by ELISA for the SS group. Disease activity (for RA, joint activity scores and extra-articular manifestations; for SLE, the SLEDAI), duration and therapy were determined.
MATERIALS AND METHODS

Subjects
Sera were collected from 120 patients with R-A, 70 patients with SLE, 27 with primary SS, each category fulfilling well-established criteria [30] [31] [32] , and 31 normal individuals. The SLE patients studied included individuals with the full range of disease activity, and organ involvement. Cases of early rheumatic disease and disease of long duration of all patient categories are included in the study.
Thirteen rheumatic disease patients from practices in Montreal, Quebec, and London, UK, were identified who had B-or T-cell lymphoma, or another neoplasia. Of this group, seven had primary SS, three had secondary SS associated with RA, and there was one case each of RA, scleroderma and dermatomyositis. Nine of these patients had B-cell lymphomas (four of which were non-Hodgkin's), two had T-cell lymphomas, one had nasopharyngeal carcinoma and one adenocarcinoma. A control group of 52 patients with lymphoma and/or neoplasia, not associated with a rheumatic disease, was also studied. Of these 52, 39
Serological studies for viruses
Antibodies (IgG) to synthetic peptides encompassing antigenic epitopes of the EBV early antigens BHRFl (peptide designated pi7.1) and BMRF1 (peptide designated p50.10) associated with the lytic cycle were determined by ELISA in the above patients, as previously described [29, 33] . Sera were tested at a 1:10 dilution with a cut-off OD of >0.3 defined as positive. This is approximately twice the background of the negative sera for these epitopes. A greater number of sera in all groups were tested for the anti-pl7.1 response than for anti-p50.10, due to its homology with bcl-2. In a small group of patients with rheumatic disease and normal controls, an ELISA with slight modifications from the previously described method was used. In brief, the synthetic peptide (5 //g/ml) of BHRFl encompassing amino acids 63-77 ( Fig. 1 ) (Chiron Mimotopes, NC, USA) was used to coat EIA II plus ELISA plates (ICN) overnight at 4°C in 0.05 M carbonate-bicarbonate buffer (pH 9.6). After washing the plates three times with phosphate-buffered saline (PBS)/0.05% Tween 20, non-specific binding sites were blocked with 2% bovine serum albumin (BSA) (Gibco, NY, USA) in PBS/Tween for 1 h at room temperature. The plates were washed three times with PBS/Tween and 100 y\ of serum, diluted 1:10, were added to each well and then incubated for 2 h at 37°C. After three washes, the bound antibodies were detected by adding horseradish peroxidase (HRP)-conjugated, goat antihuman IgG (Tago, Burlingame, CA, USA) diluted 1:5000 in PBS for 1 h at 37°C. After washing three times, the substrate o-phenylenediamine (Sigma, St Louis, MO, USA) in 0.1 M citric acid, 0.2 M sodium phosphate (dibasic), and 0.4 /xl/ml of 30% H 2 O 2 were added. The enzymatic reaction was stopped when sufficient colour was developed, by the addition of 4 M H 2 SO 4 . Absorbance at 492 nm was measured using an automatic plate reader (SLT Labinstruments, Austria). Conditions giving minimal non-specific binding were established, using 'no-antigen' or BSA-coated plates as control.
Statistical analysis
Values are expressed as the mean ± S.E.M. unless otherwise stated. Fisher's exact test, Student's r-test and other statistical comparisons were conducted (Instat, GraphPad, San Diego, CA, USA).
RESULTS
The demographic details of the patients and normal controls are presented in Table I . The duration of either the RA or SLE disease was similar (~ 13 yr), whereas patients with primary SS had a disease of slightly shorter mean duration. Thirty-seven of 91 RA patients tested were positive for RF at the time of sampling, probably a reflection of the use of methotrexate (Mtx) therapy. Of the SS patients, 4/23 (17%) were RF positive.
Whereas only one normal control was found to have antibodies to either of the EBV EA peptides derived from BHRF1 or BMRF1, a number of patients in each disease category were found to have circulating antibodies to p50.10 and/or pl7.1 (Table IT) . Of the rheumatic disease groups tested, those with either primary SS and/or lymphoma had a significantly higher frequency of circulating anti-pl7.1 antibodies, compared to the normal controls. Compared to the control group of non-rheumatic lymphoma patients, the frequency in the rheumatic disease patients with lymphoma was 2-fold higher, although this value was not significant, due to the small number of patients.
In the primary SS group, 10 of 22 patients had antibodies to Ro/SS-A and/or La/SS-B; however, there was no association between autoantibody status (including RF) and the presence of the anti-EBV EA antibodies. There was also no association between disease duration and the presence of anti-pl7.1 or anti-50.10 antibodies (data not shown). Incomplete information was available on the serum IgG levels in the SS patients, but where available there was no apparent association with total serum IgG and either antiviral antibody population (data not shown).
In the RA population, the group with compromised tear production, an indicator of SS, had a 3-fold increased frequency of anti-pl7.1 antibodies compared to those patients with normal tear production. Of the anti-EA antibody-positive RA patients with compromised tear flow, 50% had definite secondary SS. There was no significant difference in disease duration between the anti-EA antibody-positive RA patients when compared to all of the RA patients in the study (data not shown). Although disease activity scores were slightly higher for the RA subgroup with anti-p50.10 and/or pl7.1 antibodies (tenderness index 11.5 ±4.5; swelling index 15.58 ± 4.22, vs 8.8 ± 2.4 and 8.9 ± 1.4, respectively, for the RA population), only the swelling index approached significance (P = 0.062). Of the RA patients who had antibodies to pi7 and/or p50, one was receiving no therapy, three were receiving non-steroidal anti-inflammatory medications only, while the remainder were receiving disease-modifying drugs (Mtx, gold and prednisone with a maximum dose of 12.5 mg).
There was no significant difference in the serum IgG concentration between anti-p50.10 and/or anti-pl7.1 antibody-positive individuals and those without antip50 or anti-pl7 antibodies (RA patients, anti-pl7+ vs negative, 12.4 ± 2.5 and 14.0 ± 2.3 mg/dl, respectively; RA patients anti-p50+ vs negative, 13.4 ± 1.9 and 14.0 ± 2.3 mg/ml, respectively). There was no correlation between the presence of RFs and anti-pl7.1 or anti-p50.10 antibodies, with six of the 13 positive for RF.
The SLE patients were found to have a significantly increased incidence of anti-EA antibodies, compared to the RA patients, especially for anti-p50.1 (Table II) . There was, however, a significant association between the anti-p50.l0 antibodies with an elevated serum IgG (P = 0.0045; the 18 SLE patients without anti-p50.10 had a mean IgG of 13.66 ± 0.94; 18 SLE patients with anti-p50 antibodies had a mean IgG of 18.13 ± 1.13). Since p50 is a viral DNA-binding protein, we were interested to determine whether anti-p50.10 antibodies correlated with anti-DNA or anti-Ro/SS-A antibodies. No significant correlation was noted, although there was a higher frequency of anti-50.10 antibodies in those who were anti-Ro/SS-A positive (Table III) .
From the information that was available on the secondary SS status of 20 of the SLE patients, 50% met the criteria for SS [32] . Of these 20 patients, two had anti-pl7.1 antibodies and both had SS. Eleven of the 20 had antibodies to p50.10; however, there was no correlation with SS status (data not shown). Since the SLE patient population studied included individuals < 30 yr of age, where there can be a lower incidence of EBV infection, we examined the frequency of antibodies to pi7.1 and p50.10 according to age. As can be seen in Table III , there was a higher frequency of antibody positivity in the patients who were older. There was, however, no correlation between the frequency of anti-EA antibodies either to p 17 or p50 and SLE disease duration. There was no correlation between the presence of anti-pl7.1 antibodies and any autoantibody (anti-Ro/SS-A, anti-La/SS-B or anti-DNA) measured (Table III) in the SLE patients. There was no significant difference between the serum IgG in the patients with and without anti-pl7.1 antibodies.
There was an elevated percentage of the rheumatic patients with lymphoma who mounted an immune response to BHRF1, and it was of interest to see whether the antibody presence correlated with disease features. Of the rheumatic disease patients with lymphoma/neoplasia investigated, the anti-BHRFl antibody response was detected in only 2/9 (22%) of the B-cell lymphoma group. One patient with nasopharyngeal carcinoma (known to be associated with EBV) had antibodies to BMRFl/p50.1, but not to BHRFl/pl7.1. In contrast, the two patients with T-cell lymphoma and the SS patient with metastatic adenocarcinoma were anti-EA antibody negative. Previous studies had determined that one of the T-cell lymphoma patients did not have detectable EBV genome in the lymphoma, but rather had CMV [34] . As a control, a group of non-rheumatic lymphoma patients was examined and, although the majority of the anti-EA-positive individuals fell into the B-cell lymphoma group (10 and 23% positive for antiBHRFl and anti-BMRFl, respectively; n = 39), 1/7 patients with T-cell lymphoma was positive. An acute EBV infection did precede the development of lymphoma in this patient. The anti-BHRFl response was at a 4-fold higher frequency in those who had active lymphoma (5/25) compared to those in remission (1/19), but this difference was not significant.
DISCUSSION
The aetiology and progression of autoimmune rheumatic diseases are multifactorial, with genetics and environmental factors (infectious agents, therapy) playing pivotal roles. In the present study, we demonstrate that a subset of patients with primary SS, those with lymphoma, patients with RA with sicca symptoms or SLE, mount an immune response to the EBV EAs, in particular to BHRFl/pl7 and BMRF1/ p50 which are associated with the lytic cycle of viral replication. Since the pi7.1 peptide used to monitor the antibody response to the BHRF1 protein is not in the region that has been shown to be important for inhibition of apoptosis ( Fig. 1 ) and has a very low level of amino acid identity to bcl-2 (only two of the 15 amino acids in identity, with two additional conservative substitutions), it is highly unlikely that antibodies directed to this region would bind to bcl-2.
It is interesting that patients with SS mount an immune response to the EA peptides to an extent not seen in the normal or non-rheumatic lymphoma controls. It is possible that immune response genes are important in this specific recognition. In previous studies, our laboratory and others have shown that there is no difference in the frequency of the immune response to EBV proteins, such as EBNA, that are associated with latent infection in patients with rheumatic disease and normal individuals [2, 6, 9, 11] . One previous study investigated the immune response to the EBV-EA(D) (BMRFl/p50) in SLE and found that 61% of the patients had antibodies to the polypeptides of the 52-54 complex (p50) by immunoblotting, compared to 5% of the patients with mixed connective tissue disease [5] . Normal controls were not included in that study. This agrees well with our findings; however, the influence of the elevated serum IgG in the patients with SLE in the study by Ngou et al. [5] was not investigated.
In other studies, we have found that the EBV EAs are expressed in mononuclear and epithelial cells from saliva of patients with rheumatic disease [35] , and in significantly greater amounts than in normal individuals. This increased presence probably contributes to the elevated immune response and, indeed, we found a direct correlation between the detection of the anti-BHRFl antibodies in serum and the presence of the BHRF1 protein in saliva [35] .
EBV has long been associated with neoplasia, in particular Burkitt's lymphoma and nasopharyngeal carcinoma. EBV has also served as a useful tool to aid in the immortalization of human B cells. Characterization of the molecular state of the virus in the neoplasia has revealed differential expression of some viral proteins. It has been demonstrated that the EBV EAs can be detected in nasopharyngeal carcinoma [36] , as well as in lymphoma and lymphoproliferative tissue associated with immunosuppression [37] , and in the lymphomas associated with ataxia-telangiectasia [38] . BHRFl/pl7, but not BMRFl/p50, was found, however, to be expressed in most cell lines established from lymphoma biopsies [39] .
In the current study, we studied rheumatic disease patients with lymphoma, and found that those with disease that appeared to be associated with EBV mounted an immune response to BHRF1 and BMRF1. In a control group of lymphoma patients without rheumatic disease, there was a 2-fold lower incidence of antibodies to BHRF1 and to BMRF1, although the difference was not significant. This may reflect the presence of either a more fertile environment for EBV within the rheumatic diseases, possibly due to gene(s) as yet unidentified [40] , and/or a more stimulated immune response.
It is possible that BHRFl/pl7, by preventing apoptosis [16] , can contribute to the accumulation of lymphocytes and/or epithelial cells [41] that are expressing this homologue of bcl-2. This accumulation of long-living cells may increase the chance of a neoplastic event. The expression of BHRF1 itself, however, has not been found to be essential for EBV-induced B-cell transformation [42, 43] and it is unlikely that pl7 directly causes the neoplasia. It has been reported that there is defective repair of O'-methylguanine DNA in SS patients predisposed to lymphoma [44] . Since BHRFl/pl7 can protect against cell death induced by DNA-damaging agents [45] , a scenario favouring neoplasia may be favoured.
It is important to identify patients who have an increased load of BHRFl/pl7, either through direct screening of cells for BHRF1 expression and/or through anti-pl7.1 monitoring, as it may be possible to reverse the accumulation of cells in the pathological tissue by antiviral therapy. A number of cases of EBV-associated lymphomas which developed in patients with RA or dermatomyositis, receiving Mtx and/or cyclosporin therapy, have been reported. The majority of these 'induced' lymphomas reverse on discontinuation of the therapy [46] [47] [48] .
This study identifies a subgroup of rheumatic disease patients, primarily those who have SS with and without lymphoma, who mount an immune response to BHRF1, a protein that inhibits apoptosis. It is likely that the expression of BHRF1 in this setting may provide a pathological link to the lymphoproliferation or accumulation of lymphocytes unable to undergo normal apoptosis, that is commonly associated with SS, and could ultimately contribute indirectly to the development of lymphoma.
